$1.67 Billion is the total value of Frazier Life Sciences Management, L.P.'s 48 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
New | DISC MEDICINE INC | $29,082,000 | – | 655,000 | +100.0% | 1.74% | – | |
ORIC | New | ORIC PHARMACEUTICALS INC | $16,628,555 | – | 2,142,855 | +100.0% | 0.99% | – |
RETA | New | REATA PHARMACEUTICALS INCcl a | $10,239,843 | – | 100,430 | +100.0% | 0.61% | – |
DCPH | New | DECIPHERA PHARMACEUTICALS IN | $5,209,600 | – | 370,000 | +100.0% | 0.31% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ARCUTIS BIOTHERAPEUTICS INC | 7 | Q3 2023 | 17.0% |
MIRUM PHARMACEUTICALS INC | 7 | Q3 2023 | 13.6% |
PHATHOM PHARMACEUTICALS INC | 7 | Q3 2023 | 8.6% |
KRYSTAL BIOTECH INC | 7 | Q3 2023 | 7.6% |
SYNDAX PHARMACEUTICALS INC | 7 | Q3 2023 | 6.3% |
VAXCYTE INC | 7 | Q3 2023 | 4.8% |
CRINETICS PHARMACEUTICALS IN | 7 | Q3 2023 | 3.1% |
ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 3.2% |
TARSUS PHARMACEUTICALS INC | 7 | Q3 2023 | 2.5% |
KALVISTA PHARMACEUTICALS INC | 7 | Q3 2023 | 2.1% |
View Frazier Life Sciences Management, L.P.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR/A | 2023-02-07 |
13F-HR | 2023-02-03 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-10 |
13F-HR | 2022-05-16 |
View Frazier Life Sciences Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.